Our Science: Overview
BOOSTING FSH POTENCY AND EFFICACY TO TRANSFORM INFERTILITY TREATMENT
Igyxos’ differentiated approach to infertility treatment is targeted at enhancing the activity of gonadotropins – hormones that are foundational for effective reproduction. We are developing a first-in-class therapeutic monoclonal antibody (mAb), IGX12, that is designed to boost the bioactivity of Follicle Stimulating Hormone (FSH), a key hormone associated with the development of eggs in women and sperm in men. In men, FSH controls spermatogenesis. Inadequate levels of FSH create an absence of sperm production, resulting in infertility. In women, FSH controls folliculogenesis and the production of mature and fertilizable oocytes. Low levels of FSH can result in infertility because of the absence of ovulation.
Igyxos is pioneering the development of novel monoclonal antibody therapeutics that significantly improve FSH receptor activity.
CONFORMATIONAL MECHANISM OF ACTION
IGX12’s mechanism of action (MOA) is to bind to FSH and to the FSH receptor, facilitating the interaction of FSH with its receptor. This results in increased activation of the FSH receptor. Based on pre-clinical data in various animal models, our mAb therapeutic approach has the potential for treating infertility in both men and women with better effectiveness.